(Q36831348)

16 August 2017

Radiotherapy combined with gemcitabine and oxaliplatin in pancreatic cancer cells (English)

1 reference

16 August 2017

1 reference

1 reference

Meredith A Morgan

1

1 reference

16 August 2017

Amichay Meirovitz

2

1 reference

16 August 2017

Mary A Davis

3

1 reference

16 August 2017

Laura E Kollar

4

1 reference

16 August 2017

Maria C Hassan

5

1 reference

16 August 2017

Theodore S Lawrence

6

1 reference

16 August 2017

1 March 2008

1 reference

16 August 2017

Translational Oncology

1 reference

16 August 2017

1

1 reference

16 August 2017

1

1 reference

16 August 2017

36-43

1 reference

describes a project that uses

16 August 2017

ImageJ

1 reference

11 June 2022

https://www.ebi.ac.uk/europepmc/webservices/rest/PMC2510762/fullTextXML

inferred from PubMed Central ID database lookup

cites work

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2510762

H2AX phosphorylation marks gemcitabine-induced stalled replication forks and their collapse upon S-phase checkpoint abrogation

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2510762

Chemoradiotherapy with gemcitabine and continuous 5-FU in patients with primary inoperable pancreatic cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2510762

Phase II trial of induction gemcitabine/CPT-11 followed by a twice-weekly infusion of gemcitabine and concurrent external beam radiation for the treatment of locally advanced pancreatic cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2510762

Role of checkpoint kinase 1 in preventing premature mitosis in response to gemcitabine

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2510762

Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2510762

Toxicity and efficacy of concurrent gemcitabine and radiotherapy for locally advanced pancreatic cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2510762

Phase II study of gemcitabine and cisplatin in the treatment of patients with advanced pancreatic carcinoma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2510762

Eastern Cooperative Oncology Group Phase I trial of protracted venous infusion fluorouracil plus weekly gemcitabine with concurrent radiation therapy in patients with locally advanced pancreas cancer: a regimen with unexpected early toxicity

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2510762

An investigational new drug treatment program for patients with gemcitabine: results for over 3000 patients with pancreatic carcinoma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2510762

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2510762

Erlotinib and chemoradiation followed by maintenance erlotinib for locally advanced pancreatic cancer: a phase I study

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2510762

Phase I trial using a time-to-event continual reassessment strategy for dose escalation of cisplatin combined with gemcitabine and radiation therapy in pancreatic cancer

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2510762

Phase I study of concomitant gemcitabine and IMRT for patients with unresectable adenocarcinoma of the pancreatic head

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2510762

Gemcitabine, paclitaxel, and radiation for locally advanced pancreatic cancer: a Phase I trial

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2510762

Concurrent chemoradiotherapy with gemcitabine and cisplatin for pancreatic cancer: from the laboratory to the clinic

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2510762

Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer.

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2510762

Ouabain sensitizes tumor cells but not normal cells to radiation

5 September 2018

1 reference

12 December 2020

Coadministration of oxaliplatin does not influence the pharmacokinetics of gemcitabine

1 reference

12 December 2020

Radiosensitization of pancreatic cancer cells by 2',2'-difluoro-2'-deoxycytidine

1 reference

12 December 2020

Comparison of the cellular pharmacokinetics and toxicity of 2',2'-difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine

1 reference

12 December 2020

Full-dose gemcitabine and concurrent radiotherapy for unresectable pancreatic cancer

1 reference

12 December 2020

Mean inactivation dose: a useful concept for intercomparison of human cell survival curves

1 reference

12 December 2020

Oxaliplatin-induced damage of cellular DNA

1 reference

12 December 2020

Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study

1 reference

12 December 2020

Identifiers

DOI

10.1593/TLO.07106

1 reference

release_mfz4y62mbvdu3hfghzamqmcovq

16 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/mfz4y62mbvdu3hfghzamqmcovq

24 November 2022

mapped directly with Wikidata item

1 reference

16 August 2017

PubMed publication ID

18607506

1 reference